Millions of Britons regularly taking popular heartburn medications, known as proton-pump inhibitors (PPIs), are facing scrutiny from experts concerned about the long-term health implications. While these drugs, including omeprazole and lansoprazole, were hailed for their effectiveness in managing acid reflux upon their introduction in the 1990s, evidence is mounting that prolonged use may lead to serious health issues.
Approximately ten million people in the UK currently use PPIs, at an annual cost of about £300 million to the National Health Service. The concern stems from the fact that while intended for short-term use, many patients remain on these medications for years, or even decades. Experts argue that PPIs are often over-prescribed and fail to address the underlying causes of reflux, potentially leading to digestive system disruptions and increased vulnerability to infections.
Clinical gastrointestinal scientist Professor Anthony Hobson described the widespread use of PPIs as a "huge problem," stating that millions are unnecessarily taking medication that may not cure their condition and could cause harm. He noted that while PPIs are effective for short-term symptom relief, patients are frequently left on them long-term, creating secondary health problems. "It's lazy medicine," Hobson remarked, emphasizing the need for updated guidelines, increased safeguards, and greater awareness of the risks associated with these drugs.
Acid reflux, affecting about one in five Britons, occurs when stomach acid leaks into the esophagus, causing a burning sensation and chest pain. Severe cases, known as gastro-oesophageal reflux disease (GORD), can lead to esophageal damage, ulcers, and an increased risk of esophageal cancer if left untreated. Lifestyle factors such as a diet high in fatty foods, alcohol, caffeine, smoking, and obesity can exacerbate reflux. Professor Hobson suggests that for many, dietary changes, weight loss, stress reduction, and over-the-counter antacids can effectively manage symptoms.
However, the widespread availability and perceived efficacy of PPIs have led to their extensive use. These drugs work by significantly reducing stomach acid production. While a short course can allow healing of esophageal irritation, they do not resolve the root cause of reflux. A survey by The Functional Gut Clinic indicated that GPs are more likely to prescribe drugs than offer lifestyle advice, with 86 percent of patients offered medication, including 60 percent offered PPIs. Alarmingly, 34 percent of patients surveyed had been taking PPIs for over five years, and 20 percent for a decade or more.
Research has linked long-term PPI use to potential health risks. A 2017 report in the journal Gut suggested an association with an increased risk of stomach cancer. Another study published in Cureus linked PPIs to a greater risk of chronic kidney disease. Concerns have also been raised about the potential for increased risk of mental health problems and dementia, as PPIs can interfere with the body's absorption of vitamin B12, which is crucial for nervous system function and cognitive health. Stomach acid plays a vital role in breaking down food and killing ingested bacteria, and its reduction can impair the absorption of other essential nutrients like calcium and magnesium.
Professor Hobson further warned that PPIs can significantly impact the digestive system, increasing the likelihood of gut infections, such as gastroenteritis or food poisoning, by fivefold. Extended use can also damage the gut microbiome, leading to symptoms like bloating, belching, flatulence, and diarrhea, which patients may not associate with their medication. He advocates for patient and physician awareness that these symptoms could indicate a compromised gut microbiome.
While PPIs are also prescribed for indigestion, stomach ulcers, persistent coughs, and to protect the stomach from other medications like non-steroidal anti-inflammatory drugs (NSAIDs) and anticoagulants, Professor Hobson stressed that for a minority of patients, the benefits of long-term PPI use may outweigh the risks. However, he emphasized that this is often not a topic discussed with patients.
Experts are now calling for clearer official guidance for clinicians, reinforcing that PPIs are intended for short-term use. They recommend that patients taking PPIs long-term should consult their GP to discuss the necessity of the prescription, explore alternative management strategies such as dietary changes or investigations like endoscopy, and consider surgical options if appropriate. It is crucial that patients do not stop taking PPIs abruptly, as this can lead to a rebound effect of increased acid production. Gradual dose reduction under medical supervision is advised.
Jeremy Asfour, a company director, shared his experience of developing chronic kidney disease after taking omeprazole for 16 years. He believes his condition is a direct result of the long-term medication. After discontinuing the drug and gradually reducing the dosage, he has seen significant improvement in his kidney function. Asfour now manages his reflux through meditation, dietary adjustments, and avoiding late-night meals.
A spokesperson for the Medicines and Healthcare products Regulatory Agency stated that product information for all PPIs advises that patients on long-term treatment, especially beyond one year, should be under regular surveillance.